Neolife division at RPG Life Sciences was launched in July 2010. It has a range of products in the areas of chemotherapy, supportive care, and palliative care.
The division has been in line with the company's motto of launching advanced formulations with enhanced efficacy and safety. It launched NabPac, a nanoparticle bound paclitaxel, which has several advantages compared to its predecessor.
The division is looking forward to expand its biological and biosimilar portfolio. It launched HerMab, which is a biosimilar that is used in the treatment of breast cancer. The division intends to launch more biosimilars by way of in-licensing and co-development.